Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molp.2023.12.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Intravenous Patient-Controlled Analgesia for Cancer Pain: A Randomized Controlled Trial on Adjusted Background Infusion Rates.
JCO Oncol Pract
January 2025
Division of Medical Oncology, Yonsei Cancer Center, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose: Patient-controlled analgesia (PCA) has been considered for managing cancer pain; however, limited research has been conducted on optimizing continuous infusion rates with PCA. This study aimed to evaluate the efficacy and safety of a method that optimizes background infusion (BI) alongside PCA for titrating intravenous (IV) morphine in managing cancer-related pain.
Methods: Forty-four patients with solid tumors who could not manage pain with oral or transdermal opioid analgesics were randomly assigned in a 1:1 ratio to receive IV morphine through PCA or the conventional method.
Background: The approval of anti-amyloid therapies has led to a breakthrough in the treatment of Alzheimer's disease. However, given these treatments remain expensive and are associated with significant side effects, identifying patients that would, and importantly would not, benefit from treatment is crucial in optimizing costs and minimizing health risks. QyPredict®, an advanced machine learning-based predictive platform, has the potential to identify patients most likely to show cognitive decline, and may prove beneficial at prioritizing patient selection for therapies.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
University of Texas Medical Branch, Galveston, TX, USA.
Background: Chronically reactivating Herpes Simplex Virus Type 1 (HSV1) infection has been shown to produce key molecular and behavioral markers of Alzheimer's disease (AD). Most notably, the accumulation of neurotoxic tau isoforms, neurofibrillary tangles (NFTs), and Amyloid-beta plaques. Our study takes a unique approach to the systematic characterization of HSV1 biomarkers within the brain.
View Article and Find Full Text PDFBackground: Alzheimer's Disease community care is rapidly evolving as investigative therapies receive approvals and many more investigative molecules continue to show promising late phase data. While interventional approaches have been shown to have real clinical application, implementation of new diagnostics such as blood-based biomarkers for beta-amyloid confirmation has lagged in the community setting. This narrative explores Alzheimer's biomarkers within the SiteRx Alzheimer's Real-World Data network, the challenges stakeholders (physicians, patients, and biomarker infrastructure) are facing, and best practices for adoption of continually emerging interventions and diagnostics.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) affects millions of Americans, with potential future increases without breakthroughs in treatment. IGC-AD1, a novel formulation comprising of delta-9 tetrahydrocannabinol ("THC") and melatonin, is being studied in AD-associated agitation. THC is predominantly metabolized by cytochrome P450 and specifically by CYP2C9.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!